文献速递心力衰竭与心肌病

肺动脉压力引导管理用于射血分数降低的心力衰竭患者

Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

CHAMPION试验预设亚组分析纳入456例HFrEF患者,对比肺动脉压力引导管理与对照组。治疗组心衰住院率降低28%(HR 0.72,95%CI 0.59-0.88,p=0.0013),死亡风险有降低32%的趋势(HR 0.68,95%CI 0.45-1.02,p=0.06)。在基线接受GDMT的患者中,住院和死亡风险进一步降低。

要点

  • 肺动脉压力引导管理使HFrEF患者心衰住院率降低28%。
  • 基线接受GDMT者住院风险降低33%、死亡风险降低47%。
  • 同时接受ACEI/ARB和β受体阻滞剂者住院风险降低43%。

核心结论

  • 肺动脉压力引导的心衰管理可降低接受GDMT的HFrEF患者的住院率和死亡率。

研究设计与样本

  • CHAMPION试验的预设亚组分析,纳入550例慢性心衰患者,其中456例为HFrEF(LVEF≤40%)。
  • 事后分析纳入445例基线至少接受一种GDMT的患者及337例接受双联GDMT的患者。

主要发现

  • 456例HFrEF患者中,治疗组心衰住院率较对照组低28%(HR 0.72;95%CI 0.59-0.88;p=0.0013)。
  • HFrEF患者死亡风险有降低32%的趋势(HR 0.68;95%CI 0.45-1.02;p=0.06)。
  • 445例基线接受至少一种GDMT的患者,心衰住院率降低33%(HR 0.67;95%CI 0.54-0.82;p=0.0002),死亡率降低47%(HR 0.63;95%CI 0.41-0.96;p=0.0293)。
  • 337例接受双联最佳GDMT的患者,心衰住院率降低43%(HR 0.57;95%CI 0.45-0.74;p<0.0001),死亡率降低57%(HR 0.43;95%CI 0.24-0.76;p=0.0026)。

关键数值与推荐

  • HFrEF定义为左心室射血分数≤40%。
  • GDMT包括血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂或β受体阻滞剂。

临床怎么用

  • 对于HFrEF患者,在GDMT基础上可考虑肺动脉压力远程监测以进一步降低心衰住院风险。
  • GDMT耐受性越好的患者,肺动脉压力引导管理的获益可能越大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite increased use of guideline-directed medical therapy (GDMT), some patients with heart failure and reduced ejection fraction (HFrEF) remain at high risk for hospitalization and mortality. Remote monitoring of pulmonary artery (PA) pressures provides clinicians with actionable information to help further optimize medications and improve outcomes. OBJECTIVES: CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients trial) analyzed PA pressure-guided heart failure (HF) management in patients with HFrEF based on their ability to tolerate GDMT. METHODS: CHAMPION enrolled 550 patients with chronic HF regardless of left ventricular ejection fraction. A pre-specified sub-group analysis compared HF hospitalization and mortality rates between treatment and control groups in HFrEF patients (left ventricular ejection fraction ≤40%). Post hoc analyses in patients who tolerated GDMT were also performed. Hospitalizations and mortality were assessed using Andersen-Gill and Cox proportional hazards models. RESULTS: In 456 patients with HFrEF, HF hospitalization rates were 28% lower in the treatment group than in the control group (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.59 to 0.88; p = 0.0013), with a strong trend for 32% lower mortality (HR: 0.68; 95% CI: 0.45 to 1.02; p = 0.06). A 445-patient subset received at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or beta-blocker) at baseline; these patients had 33% lower HF hospitalization rates (HR: 0.67; 95% CI: 0.54 to 0.82; p = 0.0002) and 47% lower mortality (HR: 0.63; 95% CI: 0.41 to 0.96, p = 0.0293) than controls. Compared with controls, patients receiving both components of optimal GDMT (n = 337) had 43% lower HF hospitalizations (HR: 0.57; 95% CI: 0.45 to 0.74; p < 0.0001) and 57% lower mortality (HR: 0.43; 95% CI: 0.24 to 0.76; p = 0.0026). CONCLUSIONS: PA pressure-guided HF management reduces morbidity and mortality in patients with HFrEF on GDMT, underscoring the important synergy of addressing hemodynamic and neurohormonal targets of HF therapy. (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients [CHAMPION]; NCT00531661).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Givertz MM, Stevenson LW, Costanzo MR, et al. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2017. PMID: 28982501. doi:10.1016/j.jacc.2017.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。